HMGB1 and Hepatic failure: To be gratified, the last decade has witnessed the rapid development of diverse histone-neutralizing agents and HMGB1 antagonists to alleviate the immunopathological processes induced by such DAMPs and thus to improve the outcome of sepsis [12, 24], liver failure [25, 26] and pancreatitis [27, 28] animal models.